▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Spikevax XBB.1.5 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Spikevax bivalent Original/Omicron BA.4-5 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Spikevax bivalent Original/Omicron BA.1 is indicated as a booster dose for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older, who have previously received at least a primary vaccination course against COVID-19.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Spikevax is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older.

Spikevax XBB1.5 will be supplied to Northern Ireland under the provisions of NIMAR (Northern Ireland MHRA Authorised Route).

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Spikevax XBB.1.5 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Spikevax bivalent Original/Omicron BA.4-5 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Spikevax bivalent Original/Omicron BA.1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against COVID-19.

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

Spikevax is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/

By reporting side effects you can help provide more information on the safety of this medicine.

To report a product quality complaint or for general medical information inquiries, please contact Moderna on 0800 085 7562 or at EMEAMedinfo@modernatx.com.